Prolia vs. Evenity

See how Prolia and Evenity compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Prolia is injected twice a year and covers more osteoporosis indications, including men and people on steroids, while Evenity is approved only for postmenopausal women.

  • Evenity is the only drug that builds new bone and slows bone loss at the same time, but its use is capped at 12 monthly doses over a lifetime.

  • Evenity carries a boxed warning for heart attack, stroke, and cardiovascular death, while Prolia's boxed warning concerns severe low calcium in advanced kidney disease.

Prolia vs. Evenity Drug Summary

Prolia

Prolia (denosumab) is a RANK ligand inhibitor, a monoclonal antibody that slows bone breakdown, used to treat osteoporosis in postmenopausal women, men, and people with bone loss from steroids or certain cancer therapies. It is given as a single injection under the skin once every six months by a healthcare provider.

Evenity

Evenity (romosozumab-aqqg) is a sclerostin inhibitor, a monoclonal antibody that both builds new bone and reduces bone breakdown, approved for postmenopausal women with osteoporosis at high risk for fracture. It is given as two injections under the skin once a month, for a maximum of 12 doses in a patient's lifetime.

Prolia vs. Evenity Side Effects

Prolia

Most common
back pain (up to 34.1%)
pain in extremity (up to 11.4%)
musculoskeletal pain (up to 7.4%)
hypercholesterolemia (up to 7.2%)

Evenity

Most common
arthralgia (up to 13.1%)
headache (up to 5%)
injection site reactions (up to 4.9%)
nasopharyngitis (up to 2%)

Prolia vs. Evenity Dosage

Prolia

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 60 mg At the start
Maximum dose 60 mg Same as starting
Dose changes None Fixed dose

Evenity

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 210 mg At the start
Maximum dose 210 mg Same as starting
Dose changes None Fixed dose

Prolia vs. Evenity Indications

Prolia

Prolia is approved for a wide range of osteoporosis-related conditions, including postmenopausal women, men, and people with bone loss caused by steroids or cancer treatment. It is typically used long-term, with injections continuing every six months for as long as fracture risk remains high.

  • Postmenopausal women with osteoporosis at high risk for fracture

  • Men with osteoporosis at high risk for fracture

  • Glucocorticoid-induced osteoporosis in men and women

  • Men on androgen deprivation therapy for prostate cancer

Evenity

Evenity is approved only for postmenopausal women with osteoporosis who are at high risk for fracture, based on a prior fracture, multiple risk factors, or a lack of response to other treatments. Treatment is limited to one year of monthly injections, after which patients typically switch to a drug like Prolia to maintain the bone gains.

  • Postmenopausal women with osteoporosis at high risk for fracture

  • History of a prior osteoporotic fracture

  • Multiple risk factors for fracture

  • Failure or intolerance to other osteoporosis therapies

Prolia vs. Evenity Pros and Cons

Prolia

Prolia has a long track record since its 2010 approval and covers the broadest range of osteoporosis indications, including men and steroid-induced bone loss. Its main risks are rare but serious, including jaw bone problems and a rebound fracture risk if doses are missed or treatment is stopped abruptly.

Pros

  • Injected only twice a year, one of the least frequent schedules in osteoporosis treatment

  • FDA-approved for men, glucocorticoid-induced osteoporosis, and cancer-related bone loss, not just postmenopausal women

  • No boxed warning for cardiovascular events

Cons

  • Carries a boxed warning for severe low calcium in patients with advanced kidney disease

  • Stopping treatment without follow-up therapy can trigger rebound vertebral fractures

  • Linked to jawbone problems and unusual thigh bone fractures with long-term use

  • Must be administered by a healthcare professional, never self-injected at home

Evenity

Evenity is the only drug that builds new bone while also slowing its breakdown, which can make it a strong option for patients at very high fracture risk. Its cardiovascular boxed warning and one-year treatment cap mean it is usually used for a defined course before switching to a maintenance therapy.

Pros

  • Only FDA-approved therapy that both builds new bone and blocks bone breakdown

  • Treatment is capped at 12 monthly doses, giving a clear, defined stopping point

  • Once-monthly injections offer a more frequent, consistent dosing rhythm

Cons

  • Carries a boxed warning for increased risk of heart attack, stroke, and cardiovascular death

  • Not approved for men, premenopausal women, or women who may become pregnant

  • Requires two separate injections at every monthly visit

  • Roughly $1,825 to $2,629 per month before insurance or savings programs, a higher ongoing cost than Prolia's twice-yearly dosing

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.